Erin Kimbrel is currently serving as Executive Director for Regenerative Medicine at Astellas Institute for Regenerative Medicine (AIRM), an indirect, wholly-owned subsidiary of Astellas Pharma located in Westborough, Massachusetts, USA. Dr. Kimbrel has nearly 20 years of experience in the stem cell field, including several years in industry where she has been engaged in research and development of hESC and iPSC-derived cell-based therapies across multiple therapeutic areas. She was previously Senior Director of Development at Ocata Therapeutics, and prior to that, Director of MSC Research at Advanced Cell Technology. She is a co-author on over 25 publications and an inventor on numerous patents. Dr. Kimbrel is a former Fulbright scholar and member of Phi Beta Kappa, receiving her B.A. Magna Cum Laude from Holy Cross College in Worcester, Massachusetts and her Ph.D. in Pharmacology and Cancer Biology from Duke University in Durham, North Carolina. She completed post-doctoral training in Boston, Massachusetts at the Dana-Farber Cancer Institute and Harvard Medical School with a focus on hematopoietic stem cell fate decisions. Her current role at AIRM involves the strategic planning of pipeline programs as well as managing teams of scientists involved in regenerative medicine research and early product development.
This speaker appears at this event:
Erin Kimbrel, PhD
Executive Director, Regenerative Medicine, Astellas Institute for Regenerative Medicine